Under this agreement, The Ohio State University Wexner Medical Center will implement and validate DoMore Diagnostics' Histotype Px® Colorectal digital biomarker in a group of U.S. patients to determine whether the test can help guide real-life decisions for patients with stage II and stage III colorectal cancer.

DoMore Diagnostics is pleased to announce the appointment of Andreas Berg Storsve, PhD as VP Operations. Dr. Storsve will join the management team and take a leading role in driving partnerships and business development activities forward.

DoMore Diagnostics today announced that the quality management system (QMS) has been certified as compliant with the ISO 13485 standard. The certification audit process was conducted by DNV (notified body).

DoMore Diagnostics announces Dr. Takayuki Yoshino, MD, Professor Hans-Joachim Schmoll, MD, Dr. Jakob Nikolas Kather, MD, and Dr. Marc Peeters, MD are joining the Scientific Advisory Board. The four leaders in GI oncology will undoubtedly make vital contributions in bringing the company forward.

DoMore Diagnostics today announced that its Histotype Px Colorectal outcome prediction marker is available on the Sectra pathology imaging platform, facilitating seamless and easy access to this cutting-edge technology.

DoMore Diagnostics today announced that The Lancet Oncology has published an article documenting that the Histotype Px Colorectal algorithm even more accurately predicts patient outcomes when used in combination with tumor and lymph node status.